Harlan Waksal - Jan 31, 2023 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
Executive Chair, Director
Signature
/s/ Jason Cavalier, Attorney-in-Fact for Harlan Waksal, M.D.
Stock symbol
LYRA
Transactions as of
Jan 31, 2023
Transactions value $
$0
Form type
4
Date filed
2/2/2023, 04:19 PM
Previous filing
Jun 21, 2022
Next filing
Nov 13, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Stock Option Award $0 +200K $0.00 200K Jan 31, 2023 Common Stock 200K $2.85 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 31, 2023.